US 11,655,290 B2
Anti-CSP antibodies
Daniel Eric Emerling, San Carlos, CA (US); Randal R. Ketchem, Snohomish, WA (US); Shaun M. Lippow, San Carlos, CA (US); Wayne Volkmuth, San Carlos, CA (US); and Katherine L. Williams, San Carlos, CA (US)
Assigned to Atreca, Inc., San Carlos, CA (US)
Filed by Atreca, Inc., San Carlos, CA (US)
Filed on Jun. 16, 2022, as Appl. No. 17/842,351.
Claims priority of provisional application 63/211,820, filed on Jun. 17, 2021.
Prior Publication US 2023/0002483 A1, Jan. 5, 2023
Int. Cl. C07K 16/00 (2006.01); A61K 39/395 (2006.01); C07K 16/20 (2006.01); A61P 33/06 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/205 (2013.01) [A61P 33/06 (2018.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/92 (2013.01)] 31 Claims
 
1. A recombinant anti-circumsporozoite (CSP) antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein:
a) the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 3; and the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 4, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 6;
b) the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 183, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 184, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 185; and the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 186, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 187, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 188;
c) the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 205, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 206, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 207; and the heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 208, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 209, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 210.